108 related articles for article (PubMed ID: 1491726)
1. Studies on the natural killer cell activity of human nonadherent mononuclear cells (nMNC) with tumor necrosis factor, interleukin-1, interferon-gamma and cisplatin.
Pai K; Sodhi A
Neoplasma; 1992; 39(6):363-7. PubMed ID: 1491726
[TBL] [Abstract][Full Text] [Related]
2. Studies on the release of interleukin-1 (IL-1), tumor necrosis factor (TNF) and lysozyme from human non-adherent mononuclear cells (nMNC) in vitro after treatment with cisplatin and other biological response modifiers.
Sodhi A; Pai K
Neoplasma; 1992; 39(4):211-7. PubMed ID: 1436230
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2.
Ostensen ME; Thiele DL; Lipsky PE
J Biol Response Mod; 1989 Feb; 8(1):53-61. PubMed ID: 2493514
[TBL] [Abstract][Full Text] [Related]
4. Studies on the intracellular Ca2+, protein kinase activity, and ATP contents of cisplatin- and rIFN-Y-treated non-adherent mononuclear cells.
Pai K; Sodhi A
Biochem Int; 1992 May; 26(6):1017-24. PubMed ID: 1632798
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
Ostensen ME; Thiele DL; Lipsky PE
J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
[TBL] [Abstract][Full Text] [Related]
6. Effects of biological response modifiers on lung natural killer activity.
Lauzon W; Lemaire I
Immunopharmacol Immunotoxicol; 1991; 13(3):237-50. PubMed ID: 1719060
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-1.
Morikawa K; Fidler IJ
J Biol Response Mod; 1989 Apr; 8(2):206-18. PubMed ID: 2499665
[TBL] [Abstract][Full Text] [Related]
8. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
9. Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages.
Hori K; Mihich E; Ehrke MJ
Cancer Res; 1989 May; 49(10):2606-14. PubMed ID: 2496917
[TBL] [Abstract][Full Text] [Related]
10. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha.
Langermans JA; Van der Hulst ME; Nibbering PH; Hiemstra PS; Fransen L; Van Furth R
J Immunol; 1992 Jan; 148(2):568-74. PubMed ID: 1729374
[TBL] [Abstract][Full Text] [Related]
12. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
[TBL] [Abstract][Full Text] [Related]
13. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
14. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro.
Ghoneum M; Jewett A
Cancer Detect Prev; 2000; 24(4):314-24. PubMed ID: 11059563
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
Utsugi T; Sone S
J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex.
Bermudez LE; Young LS
J Immunol; 1988 May; 140(9):3006-13. PubMed ID: 2834450
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
18. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
19. Activation of human natural killer cells by lipopolysaccharide and generation of interleukin-1 alpha, beta, tumour necrosis factor and interleukin-6. Effect of IL-1 receptor antagonist.
Conti P; Dempsey RA; Reale M; Barbacane RC; Panara MR; Bongrazio M; Mier JW
Immunology; 1991 Aug; 73(4):450-6. PubMed ID: 1833315
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
